Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: A randomized trial

Annals of Internal Medicine

Volumn 157, Issue 2, 2012, Pages 94-103

  Schaefer, Martin ^a   Sarkar, Rahul ^b   Knop, Viola ^c   Effenberger, Susanne ^d   Friebe, Astrid ^e   Heinze, Loni ^d   Spengler, Ulrich ^f   Schlaepfer, Thomas ^f   Reimer, Jens ^g   Buggisch, Peter ^h   Ockenga, Johann ⁱ   Link, Ralph ^j   Rentrop, Michael ^k   Weidenbach, Hans ^l   Fromm, Gwendolyn ^m   Lieb, Klaus ⁿ   Baumert, Thomas F ^o   Heinz, Andreas ^d   Discher, Thomas ^p   Neumann, Konrad ^d   Zeuzem, Stefan ^c   Berg, Thomas ^q   more..

^a KLINIKEN ESSEN MITTE   (Germany)

^b Asklepios Westklinikum Hamburg   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e ST JOSEF HOSPITAL   (Germany)

^f UNIVERSITY HOSPITAL BONN   (Germany)

^g UNIVERSITY OF HAMBURG   (Germany)

^h DEPARTMENT OF CARDIOLOGY   (Germany)

ⁱ KLINIKUM BREMEN MITTE   (Germany)

^j St Josefsklinik ^*  (Germany)

^k TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^l Klinikum Mittelbaden   (Germany)

^m JUSTUS LIEBIG UNIVERSITY   (Germany)

ⁿ UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^o UNIVERSITY OF FREIBURG   (Germany)

^p UNIVERSITY HOSPITAL GIESSEN   (Germany)

^q UNIVERSITY HOSPITAL LEIPZIG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PLACEBO;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEART DISEASE; HEPATITIS C; HUMAN; INCIDENCE; INSOMNIA; IRRITABILITY; MALE; MENTAL DISEASE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; NERVOUSNESS; NEUROLOGIC DISEASE; NEUTROPENIA; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RISK FACTOR; SECONDARY ANALYSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84863896049     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-157-2-201207170-00006     Document Type: Article

References (35)

1. Nelson DR. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 nai{dotless}̈ve patients. Liver Int. 2011;31 Suppl 1:53-7. [PMID: 21205138]
2. Schaefer M, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Schmidt F, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:731-46. [PMID: 12188106]
3. Reichenberg A, Gorman JM, Dieterich DT. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS. 2005;19 Suppl 3:S174-8. [PMID: 16251815]
4. Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol. 2005;42:793-8. [PMID: 15885349]
5. Schäfer A, Wittchen HU, Seufert J, Kraus MR. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C-a critical review. Int J Methods Psychiatr Res. 2007;16:186-201. [PMID: 18188838]
6. Leutscher PD, Lagging M, Buhl MR, Pedersen C, Norkrans G, Langeland N, et al; NORDynamIC Group. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology. 2010;52:430-5. [PMID: 20683942]
7. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005;66:41-8. [PMID: 15669887]
8. Sockalingam S, Links PS, Abbey SE. Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. J Viral Hepat. 2011;18: 153-60. [PMID: 21070503]
9. de Knegt RJ, Bezemer G, Van Gool AR, Drenth JP, Hansen BE, Droogleever Fortuyn HA, et al. Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferonalfa-2a and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther. 2011;34: 1306-17. [PMID: 21999489]
10. Diez-Quevedo C, Masnou H, Planas R, Castellvi{dotless}́ P, Giménez D, Morillas RM, et al. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72:522-8. [PMID: 21034680]
11. Gleason OC, Fucci JC, Yates WR, Philipsen MA. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C-A pilot study. Dig Dis Sci. 2007;52:2557-63. [PMID: 17436092]
12. Kraus MR, Schäfer A, Al-Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat. 2005;12:96-100. [PMID: 15655055]
13. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord. 2007;103:83-90. [PMID: 17292481]
14. Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, et al. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics. 2010;51:401-8. [PMID: 20833939]
15. Raison CL, Woolwine BJ, Demetrashvili MF, Borisov AS, Weinreib R, Staab JP, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007;25: 1163-74. [PMID: 17451562]
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Text Revision. 4th ed. Washington, DC: American Psychiatric Assoc; 1994.
17. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33. [PMID: 9881538]
18. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Pr; 1996.
19. Lux V, Aggen SH, Kendler KS. The DSM-IV definition of severity of major depression: inter-relationship and validity. Psychol Med. 2010;40:1691-701. [PMID: 20056021]
20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9. [PMID: 444788]
21. Zimmerman M, Posternak MA, Chelminski I. Implications of using different cut-offs on symptom severity scales to define remission from depression. Int Clin Psychopharmacol. 2004;19:215-20. [PMID: 15201568]
22. Ware JE, Kosinski M, Keller SK. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston: The Health Institute; 1994.
23. Müller MJ, Himmerich H, Kienzle B, Szegedi A. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J Affect Disord. 2003;77:255-60. [PMID: 14612225]
24. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443-51. [PMID: 12540795]
25. Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007;46:991-8. [PMID: 17668880]
26. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26:643-52. [PMID: 11927189]
27. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011;130:226-38. [PMID: 21334376]
28. Kraus MR, Schäfer A, Schöttker K, Keicher C, Weissbrich B, Hofbauer I, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut. 2008;57: 531-6. [PMID: 18079286]
29. Mann JJ. The medical management of depression. N Engl J Med. 2005;353: 1819-34. [PMID: 16251538]
30. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology. 2007;45:806-16. [PMID: 17326207]
31. Sockalingam S, Abbey SE, Alosaimi F, Novak M. A review of sleep disturbance in hepatitis C. J Clin Gastroenterol. 2010;44:38-45. [PMID: 19730115]
32. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-17. [PMID: 21449784]
33. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-16. [PMID: 21696307]
34. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206. [PMID: 21449783]
35. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417-28. [PMID: 21696308]